Abstract：Objective To observe the temporal modification of transcription factor Mef2c by histone acetylases (HATs) P300, PCAF, and SRC1 during cardiogenesis and to provide a basis for investigating the pathogenesis of congenital heart disease. Methods The normal heart tissues from embryonic mice (embryonic days 14.5 and 16.5) and neonatal mice (postnatal days 0.5 and 7) were collected. The binding of P300, PCAF, and SRC1 to Mef2c gene and level of histone H3 acetylation in the promoter region of Mef2c were evaluated by chromatin immunoprecipitation assays. Meanwhile, real-time PCR was used to measure the mRNA expression of Mef2c. Results P300, PCAF, SRC1 were involved in histone acetylation in the promoter region of Mef2c during cardiogenesis in mice, and binding of P300, PCAF, and SRC1 to the promoter of Mef2c varied significantly in different stages of cardiogenesis (PPPConclusions The mRNA expression of Mef2c varies during cardiogenesis in mice, which indicates that Mef2c plays an important role in the process of cardiac development. Meanwhile, histone acetylation in the promoter region of Mef2c is regulated temporally by HATs P300, PCAF, and SRC1.
PENG Chang,ZHANG Wei-Hua,PAN Bo et al. Temporal regulation of transcription factor Mef2c by histone acetylases during cardiogenesis[J]. CJCP, 2014, 16(4): 418-423.
van der Linde D, Konings EE, Slager MA, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis[J]. J Am Coll Cardiol, 2011, 58(21): 2241-2247.
[2]
He Y, Wang J, Gu X, et al. Application of spatio-temporal image correlation technology in the diagnosis of fetal cardiac abnormalities[J]. Exp Ther Med, 2013, 5(6): 1637-1642.
[3]
Lockhart MM, Wirrig EE, Phelps AL, et al. Mef2c regulates transcription of the extracellular matrix protein cartilage link protein 1 in the developing murine heart[J]. PLoS One, 2013, 8(2): e57073.
[4]
Xin M, Olson EN, Bassel-Duby R. Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair[J]. Nat Rev Mol Cell Biol, 2013, 14(8): 529-541.
[5]
Voronova A, Al MA, Fischer A, et al. Gli2 and MEF2C activate each other's expression and function synergistically during cardiomyogenesis in vitro[J]. Nucleic Acids Res, 2012, 40(8): 3329-3347.
[6]
Huang JB, Liu YL, Sun PW, et al. Molecular mechanisms of congenital heart disease[J]. Cardiovasc Pathol, 2010, 19(5): e183-e193.
Olson EN. Gene regulatory networks in the evolution and development of the heart[J]. Science, 2006, 313(5795): 1922-1927.
[9]
Vong LH, Ragusa MJ, Schwarz JJ. Generation of conditional Mef2cloxP/loxP mice for temporal-and tissue-specific analyses[J]. Genesis, 2005, 43(1): 43-48.
[10]
Zeisberg EM, Ma Q, Juraszek AL, et al. Morphogenesis of the right ventricle requires myocardial expression of Gata4[J]. J Clin Invest, 2005, 115(6): 1522-1531.
[11]
Qin X, Xing Q, Ma L, et al. Genetic analysis of an enhancer of the NKX2-5 gene in ventricular septal defects[J]. Gene, 2012, 508(1): 106-109.
[12]
Granados-Riveron JT, Pope M, Bu'lock FA, et al. Combined mutation screening of NKX2-5, GATA4, and TBX5 in congenital heart disease: multiple heterozygosity and novel mutations[J]. Congenit Heart Dis, 2012, 7(2): 151-159.
[13]
Amodio V, Tevy MF, Traina C, et al. Transactivation in Drosophila of human enhancers by human transcription factors involved in congenital heart diseases[J]. Dev Dyn, 2012, 241(1): 190-199.
Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention[J]. Oncogene, 2007, 26(37): 5310-5318.
